BCL2 and cancer: The results of our meta-analysis suggested that the Bcl-2 -938 C>A polymorphism was not significantly associated with the prognosis of cancer (AA vs CA: OR = 0.99, 95%CI: 0.77–1.27, P = 0.93; AA vs CC: OR = 0.92, 95%CI: 0.65–1.30, P = 0.63; CA vs CC: OR = 0.94, 95%CI: 0.80–1.11, P = 0.48; CC vs AA+CA: OR = 1.21, 95%CI: 0.69–2.13, P = 0.50; AA vs CC+CA: OR = 0.99, 95%CI: 0.48–2.04, P = 0.97) (Figure 6).